Peptide protocols, with the evidence attached
The dosing schedule, the reconstitution maths, the vial count and the real cost, for every protocol, in one consistent format. Every number shows whether it came from an FDA label, a named trial arm, or a forum — because those are not the same thing and most sites render them identically.
The protocols people actually look up
Each one carries the full schedule, the syringe pull, the vial count and the cost at every vendors — with the source behind every figure.
Semaglutide
Semaglutide
The 16-week step-up written into the approved label, with the arithmetic done for each step.
68 weeks · 17 vials · $870.00
Wolverine Stack
BPC-157 + TB-500
The most-searched stack in this category, and the one with the least human evidence behind it.
8 weeks · 9 vials · $282.00
CJC-1295 + Ipamorelin
CJC-1295 (no DAC / Mod GRF 1-29) + Ipamorelin
The standard evening pairing. Pharmacologically coherent, clinically unproven.
12 weeks · 6 vials · $159.99
How this is different
Most peptide sites tell you what to take. This one tells you what is known.
Three commitments hold everything else together.
Graded per claim, not per compound
A compound can have strong evidence for one endpoint and none at all for another. Grading the whole compound hides that. Every claim here carries its own evidence level, its own confidence rating, and its own statement of what remains unknown.
Calculations are deterministic
Every number is produced by a tested calculation service using decimal arithmetic, never by a language model. Results are property-tested against mathematical invariants across thousands of generated cases, and nothing is ever silently rounded.
Absence of evidence is stated plainly
Where a study does not exist, we say the study does not exist. No documented interaction is never rendered as safe, and a compound missing from this catalogue is not an endorsement of it.
Explore research
Start from what you want to understand
Each topic maps to graded claims, the studies behind them, and the compounds that have been examined for that endpoint.
Metabolic & Body-Composition Research
Incretin signalling, energy balance, adiposity, glycaemic parameters, and body-composition endpoints as measured in published trials.
7 compounds catalogued
Musculoskeletal Recovery Research
Tendon, ligament, muscle, and connective-tissue repair endpoints. Note that this area is dominated by animal models.
2 compounds catalogued
Sleep & Circadian Research
Sleep architecture, slow-wave sleep, circadian signalling, and related polysomnographic endpoints.
1 compound catalogued
Cognitive & Neurologic Research
Neurotrophic signalling, memory and attention endpoints, neuroprotection, and neuroinflammation.
2 compounds catalogued
Dermatologic & Tissue Research
Dermal matrix remodelling, collagen synthesis, wound healing, pigmentation, and follicular endpoints.
2 compounds catalogued
Aging & Longevity Research
Cellular senescence, telomere biology, NAD+ metabolism, and biomarkers proposed as ageing surrogates.
2 compounds catalogued
GH-Axis Research
Growth-hormone-releasing hormone analogues, secretagogues, IGF-1 response, and pulsatility.
5 compounds catalogued
Immune Signalling Research
Thymic peptides, T-cell modulation, inflammatory signalling, and infection-related endpoints.
1 compound catalogued
Mitochondrial Research
Mitochondrial-derived peptides, cardiolipin interaction, oxidative phosphorylation, and exercise capacity.
2 compounds catalogued
Sexual Health Research
Melanocortin signalling and sexual-desire or erectile-function endpoints as measured by validated instruments.
1 compound catalogued
Research records
Where the evidence is strongest, and where it is not
These four records span the range deliberately: from large randomised trials to a compound whose human safety has never been characterised.
Semaglutide
A long-acting GLP-1 receptor agonist. Among the most extensively studied compounds in this catalogue, with large randomised trials and regulatory approval for specific indications.
2 human studies · 2 graded claims
Tirzepatide
A dual incretin receptor agonist with large randomised evidence including a 176-week readout that also reported post-withdrawal weight regain.
2 human studies · 2 graded claims
BPC-157
One of the most discussed compounds in this category and one of the least supported by human evidence. The published record is overwhelmingly animal work.
2 human studies · 2 graded claims
Epitalon
Widely marketed for longevity. The evidence originates almost entirely from a single research programme and has not been independently replicated.
1 human study · 1 graded claim
Research tools
Deterministic calculators, not guesswork
Every tool shows the arithmetic that produced its result, discloses rounding, and refuses inputs that cannot produce a valid answer.
Solution calculator
Concentration, required volume, and a live measurement-device visualiser with exact value and readable graduation shown separately.
Supplies planner
Containers, solvent, and disposables for a schedule you define, with every step of the arithmetic exposed.
Concentration decay
Illustrates published half-life figures, accumulation across repeated events, and time to steady state.
Schedule projection
Converts a schedule you already have into dates and a calendar file. It does not decide the schedule.
Cost model
Cost per event, per day, and per month from prices you enter.
Interaction explorer
Pairwise evaluation from a curated register. Severity and certainty stay separate.
Coverage
Complete catalogue. Honest about which parts are reviewed.
We catalogue all 161 compounds listed across the 9 leading peptide catalogues, deduplicated by alias. What we will not do is pretend that listing something is the same as knowing something about it.
Individually graded claims, a study register with verification status, reported study parameters, safety signals, and an explicit account of what remains unestablished.
What the molecule is, and which catalogues sell it. No grade, no quantity, no claim, because no review has been done. You get a link to the primary literature instead of a summary we cannot stand behind.
What this platform is not